"The Voice" Winner, Javier Colon, to Perform in Tribute Concert Honoring Stevie Wonder at the 15th Annual Multiple Myeloma Research Foundation (MMRF) Fall Gala

Michael McDonald, Darius Rucker and Javier Colon Unite to Perform at Premier Event Raising Urgent Funds for Cancer Research

Norwalk, CT — September 30, 2011

Multiple Myeloma Research Foundation (MMRF) announced today that Javier Colon, winner of NBC’s The Voice, will join the lineup of featured artists performing a tribute concert celebrating music industry icon Stevie Wonder at the MMRF Fall Gala, to be held October 29, 2011, at the Hyatt Regency Greenwich in Old Greenwich, Connecticut. The MMRF will honor Stevie Wonder with the MMRF Spirit of Hope Award, presented annually to individuals who inspire hope with their perseverance in overcoming personal obstacles. All funds raised at the Gala will support the development of next-generation treatments for multiple myeloma, an incurable blood cancer.

In August 2011, Javier Colon was nominated for the Teen Choice Awards Breakout Artist of the Year following his June 2011 win on the inaugural season of NBC’s The Voice. Colon, who grew up in Connecticut’s Fairfield County, formerly performed as lead singer for The Derek Trucks Band and EmCQ, a neo-funk group dedicated to the legacy of Stevie Wonder among others. Colon’s debut album with Universal Republic Records is slated for a November 2011 launch. As previously announced, Michael McDonald and Darius Rucker will also perform at the MMRF Fall Gala as featured artists in the tribute concert to Stevie Wonder.

“I am honored to have the opportunity to participate with Michael McDonald and Darius Rucker in this tribute concert for Stevie Wonder,” said Colon. “The MMRF is one of the nation’s most groundbreaking cancer research organizations and I hope that our involvement will help find a cure for this rare cancer.”

The MMRF has facilitated unprecedented accomplishments such as helping to bring four new myeloma drugs to market, more than doubling the patient life expectancy post-diagnosis, opening 32 clinical trials 60% faster than industry standard in oncology, and sequencing the multiple myeloma genome. The four treatments the MMRF helped accelerate are now standard therapies for patients with multiple myeloma and are being used or explored as treatments for more than 30 other cancers.

Despite the advancements made by the MMRF, the five year survival rate for myeloma remains one of the lowest of all cancers. The funds raised by the MMRF are critical in continuing to advance research and the progress being made.

“We are so thankful to have Javier Colon, Michael McDonald and Darius Rucker joining us,” said Kathy Giusti, Founder and CEO of the MMRF and a myeloma patient. “The support of these talented musicians will help the MMRF continue our urgent work to bring patients new treatments.” The MMRF Fall Gala is one of the largest fundraising events in Connecticut’s Fairfield County. Attendees include celebrities, prominent business executives and high-impact philanthropists. To reserve a table, donate an auction item or inquire about sponsorship opportunities, please email mmrf@benefitoffice.org or call 888-584-5463.

About Multiple Myeloma
Multiple myeloma is an incurable blood cancer. The five-year relative survival rate for multiple myeloma is approximately 38 percent, one of the lowest of all cancers. In 2011, more than 20,000 adults in the United States will be diagnosed with multiple myeloma and nearly 11,000 people are predicted to die from the disease.

About the Multiple Myeloma Research Foundation (MMRF)
The Multiple Myeloma Research Foundation (MMRF) was established in 1998 as a 501(c)3 non-profit organization by twin sisters Karen Andrews and Kathy Giusti, soon after Kathy's diagnosis with multiple myeloma. The mission of the MMRF is to relentlessly pursue innovative means that accelerate the development of next-generation multiple myeloma treatments to extend the lives of patients and lead to a cure. As the world's number-one private funder of multiple myeloma research, the MMRF has raised over $170 million since its inception to fund nearly 120 laboratories worldwide, including 70 new compounds and approaches in clinical trials and pre-clinical studies and has facilitated more than 30 clinical trials through its affiliate organization, the Multiple Myeloma Research Consortium (MMRC). As exceptional stewards of its donors' investments, the MMRF consistently surpasses its peers in fiscal responsibility. For more information about the MMRF, please visit www.themmrf.org.

Eileen Regan